Literature DB >> 9884835

Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.

M Pfaller1, J Zhang, S Messer, M Tumberland, E Mbidde, C Jessup, M Ghannoum.   

Abstract

Little is known of the antifungal susceptibility patterns and molecular epidemiology of Cryptococcus neoformans from tropical regions. We studied 164 clinical isolates of C. neofomans from 120 Ugandan AIDS patients with cryptococcal meningitis by analyzing their electrophoretic karyotypes and antifungal susceptibility profiles. Computer-assisted analysis of karyotype patterns was performed to generate dendrograms. MICs of fluconazole and flucytosine were determined by reference methods. A total of 43 distinguishable DNA types were identified among the 164 isolates. Only 30 patients (25%) were infected with their own unique strain of c. neoformans, whereas 75% of the patients shared their infecting strain with at least one other patient. Among 17 patients with more than one CSF isolate of C. neoformans, sequential isolates were identical or highly related in 12 (71%) and were different in five patients (29%). The isolates were susceptible to both fluconazole and flucytosine and there were no instances in which a stepwise increase in either fluconazole or flucytosine MICs was observed among serial isolates. These findings suggest that the epidemiology of cryptococcal disease in AIDS patients from tropical regions may be somewhat different from that observed in more temperate climates.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Bacterial And Fungal Diseases; Developing Countries; Diseases; Drugs; Eastern Africa; English Speaking Africa; Epidemiology; Health; Hiv Infections; Infections; Public Health; Research Report; Treatment; Uganda; Viral Diseases

Mesh:

Substances:

Year:  1998        PMID: 9884835     DOI: 10.1016/s0732-8893(98)00095-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  14 in total

1.  Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection.

Authors:  Kirsten Nielsen; Gary M Cox; Anastasia P Litvintseva; Eleftherios Mylonakis; Stephanie D Malliaris; Daniel K Benjamin; Steven S Giles; Thomas G Mitchell; Arturo Casadevall; John R Perfect; Joseph Heitman
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.

Authors:  Nelesh P Govender; Jaymati Patel; Marelize van Wyk; Tom M Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

3.  Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans.

Authors:  J Xu; C Onyewu; H J Yoell; R Y Ali; R J Vilgalys; T G Mitchell
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Geographic distribution of mating type alleles of Cryptococcus neoformans in four areas of the United States.

Authors:  Zhun Yan; Xiaogang Li; Jianping Xu
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients.

Authors:  C J Jessup; M A Pfaller; S A Messer; J Zhang; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans.

Authors:  Aarti Tewari; Bijayani Behera; Purva Mathur; Immaculata Xess
Journal:  Mycopathologia       Date:  2012-02-22       Impact factor: 2.574

7.  Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.

Authors:  T Yamazumi; M A Pfaller; S A Messer; A K Houston; L Boyken; R J Hollis; I Furuta; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

8.  Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis.

Authors:  María T Illnait-Zaragozí; Gerardo F Martínez-Machín; Carlos M Fernández-Andreu; Ferry Hagen; Teun Boekhout; Corné H W Klaassen; Jacques F Meis
Journal:  BMC Infect Dis       Date:  2010-10-04       Impact factor: 3.090

9.  Antifungal susceptibilities of Cryptococcus neoformans.

Authors:  Lennox K Archibald; Marion J Tuohy; Deborah A Wilson; Okey Nwanyanwu; Peter N Kazembe; Somsit Tansuphasawadikul; Boonchuay Eampokalap; Achara Chaovavanich; L Barth Reller; William R Jarvis; Gerri S Hall; Gary W Procop
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

10.  ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50.

Authors:  Elliot S Gerlach; Sophie Altamirano; J Marina Yoder; Tony S Luggya; Andrew Akampurira; David B Meya; David R Boulware; Joshua Rhein; Kirsten Nielsen
Journal:  Front Cell Infect Microbiol       Date:  2021-06-23       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.